Three words. Important differences.

Approval concerns a specific product and its reviewed uses. It is not a blanket endorsement of a molecule’s every possible use or of a different formulation. Ask for the exact product name and the relevant prescribing information when discussing a recommendation.

Compounded drugs are not FDA-approved. Compounding can address particular patient needs, but the FDA does not review each compounded drug for safety, effectiveness, and quality before marketing. A pharmacy’s 503A or 503B status does not, by itself, establish that every formulation is lawful, safe, or suitable for a particular person.

Investigational describes something being studied; it does not mean that a treatment has been proven or is available in routine care. A collection name or intended focus area does not establish a clinical trial result, a regulatory approval, or individual suitability. Each should be evaluated on the evidence relevant to the specific care decision.